Zhang Wei, Zhang Liujie, Lv Mingti, Fu Yun, Meng Xiaowen, Wang Mingyong, Wang Hecheng
School of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.
Department of Pharmacology, Qingdao University School of Pharmacy, Qingdao, China.
Curr Alzheimer Res. 2024;21(4):221-231. doi: 10.2174/0115672050329828240805074938.
Alzheimer's disease (AD) is the most common type of dementia among middle-aged and elderly individuals. Accelerating the prevention and treatment of AD has become an urgent problem. New technology including Computer-aided drug design (CADD) can effectively reduce the medication cost for patients with AD, reduce the cost of living, and improve the quality of life of patients, providing new ideas for treating AD. This paper reviews the pathogenesis of AD, the latest developments in CADD and other small-molecule docking technologies for drug discovery and development; the current research status of small-molecule compounds for AD at home and abroad from the perspective of drug action targets; the future of AD drug development.
阿尔茨海默病(AD)是中老年人群中最常见的痴呆类型。加快AD的预防和治疗已成为一个紧迫的问题。包括计算机辅助药物设计(CADD)在内的新技术可以有效降低AD患者的用药成本,降低生活成本,提高患者的生活质量,为治疗AD提供新思路。本文综述了AD的发病机制、CADD及其他用于药物发现和开发的小分子对接技术的最新进展;从药物作用靶点的角度阐述了国内外AD小分子化合物的研究现状;以及AD药物开发的未来。